Obila, 1st Pulsatile Antihistamine

ACI Pharmaceuticals launches Obila, an advanced antihistamine designed to provide chronotherapeutic control of allergic symptoms by synchronizing drug release with the body's biological rhythm. Obila is indicated for the treatment of Allergic Rhinitis, Rhinoconjunctivitis, Chronic Urticaria, and other allergic conditions.

As a next-generation pulsatile antihistamine formulation, Obila is engineered to reduce early-morning allergic surges and breakthrough symptoms, delivering sustained, full-day relief. With its innovative drug-release technology, Obila offers a superior approach to modern allergy management.